

COPD maintenance with dosing both day and night

CHOOSE **BREZTRI™** **AEROSPHERE®** FOR ITS POWER TO REDUCE EXACERBATIONS IN COPD¹



**Budesonide (ICS), glycopyrronium (LAMA),
and formoterol (LABA) in 1 pMDI device***

BREZTRI™ AEROSPHERE® is indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA.¹

ICS = Inhaled corticosteroid;
LABA = Long-acting beta₂-adrenergic agonist;
LAMA = Long-acting muscarinic antagonist;
pMDI = Pressurized metered-dose inhaler.

* Clinical significance has not been established.



BREZTRI™
AEROSPHERE®
budesonide / glycopyrronium / formoterol
fumurate dihydrate pressurized inhalation
suspension

BREZTRI™ AEROSPHERE®: TWICE-DAILY ADMINISTRATION WITH A SINGLE pMDI INHALER¹



2 inhalations
in the
morning




2 inhalations
in the
evening

PHARMACODYNAMICS: BREZTRI™ AEROSPHERE® ACHIEVED RAPID ONSET OF ACTION*



Improvement in FEV₁ within
5 minutes of the first dose on
Day 1 (median time to ≥100 mL)



Please see the Product Monograph for full dosing information.

* Clinical significance has not been established.

Consult the BREZTRI™ AEROSPHERE® Product Monograph at breztri-en.azpm.ca for important information about:

- Relevant warnings and precautions regarding risk of serious asthma-related events, deterioration of disease, excessive use with other LAMA, LABA products, anticholinergic activity, cardiovascular effects, driving and operating machinery, candidiasis, risk of systemic effects, hypercorticism and adrenal suppression, adrenal insufficiency in patients transferred from systemic steroid, patients with symptomatic prostatic hyperplasia, glaucoma, convulsive disorders, thyrotoxicosis, sensitivity to sympathomimetic amines, severe hepatic impairment/hepatic disease, or urinary retention, systemic eosinophilic conditions (in rare cases), susceptibility or decreased resistance to infections, monitoring, paradoxical bronchospasm, increased risk of pneumonia, pregnant and nursing women, geriatrics.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

The Product Monograph is also available by calling AstraZeneca Canada at **1-800-668-6000**.

Reference: 1. BREZTRI™ AEROSPHERE® Product Monograph. AstraZeneca Canada Inc., September 30, 2021.



**BREZTRI™
AEROSPHERE®**
budesonide / glycopyrronium / formoterol
fumurate dihydrate pressurized inhalation
suspension



AstraZeneca

BREZTRI™ is a trademark of AstraZeneca AB, used under license by AstraZeneca Canada Inc.
AEROSPHERE® and the AstraZeneca logo are registered trademarks of AstraZeneca AB, used under
license by AstraZeneca Canada Inc.

© AstraZeneca Canada Inc. 2022

CA-5948